News | November 24, 2014

Early Detectable Vascular Disease Linked to Erectile Dysfunction

CT calcium exam could indicate risk of developing erectile dysfunction

November 24, 2014 — Men who have asymptomatic subclinical vascular disease are more likely to develop erectile dysfunction than men who don’t have early-stage vascular disease, according to research presented at the American Heart Association’s (AHA) Scientific Sessions 2014. Data suggests use of a coronary computed tomography (CT) calcium exam may reveal the patient’s risk of developing erectile dysfunction.

“Erectile function can be a window into men’s cardiovascular and overall health,” said David I. Feldman, B.S., lead author and research assistant at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins in Baltimore, Maryland. “Erectile dysfunction and cardiovascular disease commonly co-exist.”

Researchers studied 1,862 men without existing heart disease and assessed the relationship between early atherosclerotic plaque development and arterial stiffness and dysfunction with their subsequent self-reporting of erectile dysfunction.

“We looked at which measurement of early vascular disease was the best predictor for erectile dysfunction,” Feldman said. “We also looked at whether those men with multiple abnormalities, such as increased plaque in addition to arterial stiffness and dysfunction, were more likely to also suffer from erectile dysfunction.”

Researchers found:

  • Men with coronary artery calcium scores greater than 100 Agatston units were 43 percent more likely to later self-report erectile dysfunction compared to otherwise identical men with normal calcium scores. (The Agatston Score is a measure of the amount of calcified plaque in the coronary arteries.)
  • Men who subsequently had erectile dysfunction were at least two times more likely to have coronary artery calcium scores greater than 100 Agatston units at the start of the study, which ran more than nine years.
  • While coronary artery calcium had the strongest association to erectile dysfunction, other measures of early vascular disease, including carotid intima-media thickness (cIMT), were notably worse among men with erectile dysfunction compared to those without. cIMT measures plaque build-up in your carotid arteries that supply blood to the head, neck, and brain.
  • After considering age, race, sex and traditional risk factors — such as diabetes, smoking, high cholesterol and obesity — men with abnormalities of both atherosclerosis as well arterial stiffness and dysfunction were 53 percent more likely to later self-report erectile dysfunction.

 

To improve long-term erectile function and reduce the risk for worsening cardiovascular health, at-risk men should eat a heart-healthy diet, engage in physical activity and avoid smoking, Feldman said.

“Current guidelines recommend exercise stress testing and an ankle-brachial index test for risk assessment in patients with erectile dysfunction,” he said. “Our results suggest a more powerful indicator is direct measurement of coronary plaque through the use of a CT coronary artery calcium test.”

More research is needed before physicians routinely use coronary artery calcium tests over other noninvasive methods to assess men’s sexual health, Feldman said. And more work needs to be done on how best to prevent erectile dysfunction in those men with confirmed asymptomatic vascular disease.

Researchers excluded men on impotence drugs and couldn’t ensure that all men were free of erectile dysfunction at the study’s baseline examination.

Co-authors are Kevin L. Billups, M.D.; Andrew P. DeFilippis, M.D.; Kanchan Chitaley, Ph.D.; Philip Greenland, M.D.; James H. Stein, M.D.; Matthew J. Budoff, M.D.; Zeina Dardari, M.S.; Roger S. Blumenthal, M.D.; Khurram Nasir, M.D., M.P.H.; and Michael J. Blaha, M.D., M.P.H. Author disclosures are on the abstract.

For more information: www.heart.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now